Uncertainty Looms Over Pfizer's Oral COVID-19 Antiviral Pill - Doubts Over Commercial Approval
Portfolio Pulse from Vandana Singh
Pfizer's CEO Albert Bourla has revealed that the company's oral antiviral COVID-19 treatment, Paxlovid, is being administered at a rate of 250,000 courses per week. However, there is uncertainty over when Paxlovid will gain approval for commercial sale in the U.S. market. Currently, the drug is being distributed exclusively by the government. Pfizer has supplied nearly 24 million courses of Paxlovid to the U.S. government, but only about 15 million courses have been distributed so far.
September 27, 2023 | 12:54 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Pfizer's Paxlovid is being administered at a high rate, but there is uncertainty over its commercial approval. This could potentially impact Pfizer's stock in the short term.
The uncertainty over the commercial approval of Pfizer's Paxlovid could potentially impact the company's stock. If the drug gains approval, it could boost Pfizer's revenues and positively impact the stock. However, if approval is delayed or denied, it could negatively impact the stock.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100